This clinical trial is focused on studying the effects of a medication called atezolizumab, which is marketed under the name Tecentriq. The study is designed for patients who have been previously involved in a study sponsored by Genentech or F. Hoffmann-La Roche Ltd. The main goal is to provide continued access to atezolizumab-based therapy for patients who were receiving it in a previous study and do not have access to it locally. The study primarily involves patients with cancer, although future studies may include other types of cancer.

Participants in this study will continue to receive atezolizumab or a comparator agent, which is another treatment used for comparison, if they were benefiting from it in the previous study. The treatment is administered as a solution for infusion, meaning it is given directly into the bloodstream through a vein. The study will observe patients over a long period to monitor their health and any side effects they may experience. This includes tracking any serious adverse events, which are unexpected medical problems that occur during treatment, and their severity.

The study will also look at the time from when patients start the treatment to when they may pass away from any cause, specifically for those who were part of a previous study called IMpower133. This trial aims to ensure that patients who were benefiting from atezolizumab can continue their treatment safely and effectively, while also gathering important information about the long-term effects of the medication.